Literature DB >> 7914094

Expression of the neomycin-resistance (neo) gene induces alterations in gene expression and metabolism.

A Valera1, J C Perales, M Hatzoglou, F Bosch.   

Abstract

The amino 3'-glycosyl phosphotransferase (neo) gene is the selectable marker most widely used in stable transfection or infection protocols. Because the neo gene product has phosphotransferase activity, it might modify the phosphorylation state when introduced in mammalian cells. NIH-3T3 fibroblast cells expressing the neo gene, after either infection with retroviral vectors or transfection with plasmids, showed a 50% reduction in both fructose 2,6-bisphosphate (Fru 2,6-P2) concentration and lactate production compared with control NIH-3T3 cells, indicating that these neo-expressing cells are less glycolytic. In addition, a marked decrease in the levels of mRNA for the procollagen 1 alpha and fibronectin genes was also observed in neo-expressing NIH-3T3 cells. This decrease was concomitant with an increase in the mRNA concentration of the endogenous c-myc gene. FTO-2B rat hepatoma cells also showed modifications in gene expression when the neo gene was introduced by stable transfection or infection. In these cells an increase in both P-enolpyruvate carboxykinase (PEPCK) and tyrosine aminotransferase (TAT) mRNA was observed. These results suggest that neo gene expression may induce changes in the cells, which should be considered when neo-selected cells are used to deliver specific genes in different therapy approaches and in embryo manipulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914094     DOI: 10.1089/hum.1994.5.4-449

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  21 in total

1.  Performance of high quality minicircle DNA for in vitro and in vivo gene transfer.

Authors:  Dennis Kobelt; Martin Schleef; Marco Schmeer; Jutta Aumann; Peter M Schlag; Wolfgang Walther
Journal:  Mol Biotechnol       Date:  2013-01       Impact factor: 2.695

Review 2.  Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.

Authors:  Juergen Mairhofer; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

3.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

Review 4.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

5.  Self-deleting retrovirus vectors for gene therapy.

Authors:  A P Russ; C Friedel; M Grez; H von Melchner
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Fitness consequences of genetically engineered herbicide and antibiotic resistance in Arabidopsis thaliana.

Authors:  C B Purrington; J Bergelson
Journal:  Genetics       Date:  1997-03       Impact factor: 4.562

7.  Development of high-titer retroviral producer cell lines by using Cre-mediated recombination.

Authors:  E F Vanin; L Cerruti; N Tran; G Grosveld; J M Cunningham; S M Jane
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.

Authors:  C L Endres; E P Bergquam; M K Axthelm; S W Wong
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

9.  Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo.

Authors:  M P Rubinstein; M L Salem; A N Kadima; C L Nguyen; W E Gillanders; M I Nishimura; D J Cole
Journal:  Cancer Gene Ther       Date:  2008-08-08       Impact factor: 5.987

10.  Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain.

Authors:  Halina Machelska; Matthias Schroff; Detlef Oswald; Waltraud Binder; Nicolle Sitte; Shaaban A Mousa; Heike L Rittner; Alexander Brack; Dominika Labuz; Melanie Busch; Burghardt Wittig; Michael Schäfer; Christoph Stein
Journal:  Mol Pain       Date:  2009-12-14       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.